Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia (AIHA) is a rare but serious hematological disorder characterized by the premature destruction of red blood cells (erythrocytes) by the body's own immune system. The immune system produces autoantibodies that bind to antigens on the surface of red blood cells, leading to their destruction (hemolysis) either in the spleen (extravascular) or within the blood vessels (intravascular). AIHA is broadly classified into "warm" or "cold" types based on the thermal reactivity of the autoantibodies involved.

AIHA can be idiopathic (primary), occurring without an identifiable underlying cause (approximately 50% of cases), or secondary to another condition.

• Genetic Factors: While not directly inherited, certain HLA types may predispose individuals to autoimmune dysregulation.


• Associated Conditions: Chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, systemic lupus erythematosus (SLE), and rheumatoid arthritis.


• Infections: Mycoplasma pneumoniae, Epstein-Barr virus (EBV), and HIV.


• Medications: Drug-induced AIHA can be triggered by penicillin, methyldopa, or fludarabine.

The core mechanism involves the loss of immune tolerance to self-antigens on red blood cells (RBCs).

• Warm AIHA (W-AIHA): Mediated by IgG antibodies that react optimally at 37°C. These IgG-coated RBCs are recognized by Fc receptors on splenic macrophages, leading to partial or complete phagocytosis and the formation of spherocytes.


• Cold AIHA (C-AIHA): Mediated by IgM antibodies (Cold Agglutinins) that react at 0°C–30°C. IgM binds RBCs in cooler peripheral circulation, fixing complement (C3b). Upon returning to warmer central circulation, the IgM dissociates, but C3b remains, leading to sequestration by hepatic Kupffer cells.

• Prevalence: Estimated at 1 to 3 cases per 100,000 people per year.
• Age: W-AIHA occurs at any age but peaks in the 50s–70s. C-AIHA is more common in the elderly (70+).
• Gender: Slight female predominance in W-AIHA; CAD shows no significant gender bias.

• Pre-existing autoimmune diseases (SLE, Evans Syndrome).
• B-cell malignancies (CLL, Lymphoma).
• Recent viral or atypical bacterial infections.
• History of organ or bone marrow transplantation.
• Exposure to specific medications (cephalosporins, NSAIDs).

• Vital Signs: Tachycardia, tachypnea, and occasionally low-grade fever.
• Inspection: Scleral icterus, mucosal pallor, and livedo reticularis (in cold AIHA).
• Palpation: Splenomegaly is common in W-AIHA; hepatomegaly may be present.
• Auscultation: Hemic systolic murmurs due to hyperdynamic circulation.

• A. Clinical Assessment: History of sudden onset fatigue, jaundice, and dark urine.
• B. Laboratory Testing: Fundamental for confirming hemolysis and immune etiology.
• C. Imaging Studies: Ultrasound or CT to assess spleen and liver size.
• D. Functional Tests: Assessment of cardiac output in severe cases.
• E. Biopsy Findings: Bone marrow biopsy may show erythroid hyperplasia.
• G. Differential Diagnosis: Ruling out non-immune causes like G6PD deficiency or microangiopathic hemolytic anemia.

Direct Antiglobulin Test (Coombs Test)

• Type: Blood Test


• Purpose: To detect autoantibodies or complement proteins on the RBC surface.


• Expected Findings: Positive for IgG (Warm) or C3 (Cold).


• Interpretation: Confirms the immune-mediated nature of the hemolysis. Serum Haptoglobin


• Type: Blood Test


• Purpose: Measure a protein that binds free hemoglobin.


• Expected Findings: Decreased or undetectable.


• Interpretation: Indicates active intravascular or significant extravascular hemolysis. Reticulocyte Count


• Type: Blood Test


• Purpose: Assess bone marrow response to RBC loss.


• Expected Findings: Significantly elevated (Reticulocytosis).


• Interpretation: Confirms that the anemia is due to destruction rather than production failure.

• Abdominal Ultrasound: Purpose is to evaluate the degree of splenomegaly. Finding a significantly enlarged spleen supports a diagnosis of W-AIHA and helps in surgical planning if splenectomy is considered.
• CT Scan (Chest/Abdomen/Pelvis): Used primarily to look for underlying lymphoproliferative disorders or occult malignancies that may be triggering secondary AIHA.

• Hereditary Spherocytosis: Characterized by spherocytes but a negative Coombs test.
• G6PD Deficiency: Hemolysis triggered by oxidative stress; positive for Heinz bodies.
• Thrombotic Thrombocytopenic Purpura (TTP): Presence of schistocytes on smear and thrombocytopenia.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): Flow cytometry shows loss of CD55/CD

• Severe anemia leading to high-output heart failure.
• Venous Thromboembolism (VTE): Hemolysis releases pro-thrombotic factors.
• Infection: Often secondary to immunosuppressive treatments or splenectomy.
• Aplastic Crisis: Rarely, if parvovirus B19 infection occurs simultaneously.

• Short-term: Most patients respond well to initial corticosteroid therapy (70-80% response rate for W-AIHA).
• Long-term: Chronic relapsing course is common in primary AIHA. Secondary AIHA prognosis depends on the management of the underlying disease. Mortality is generally low (<10%) but increases with severe complications like venous thromboembolism.

• Secondary Prevention: Early detection of underlying B-cell malignancies and autoimmune disorders.
• Screening: Regular CBC monitoring in patients with known risk factors like SLE or CLL.

The following homeopathic remedies have been historically indicated for symptoms associated with Autoimmune Hemolytic Anemia. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Anemia Severity & Type Classifier

Evaluates and classifies anemia based on Hemoglobin levels, MCV (cell volume), MCH, and Ferritin storage to detect iron deficiency or vitamin deficiencies.